Apolipoprotein C2 Deficiency Treatments

Find Apolipoprotein C2 Deficiency Treatments

Brand Name

Redemplo

Generic Name
Plozasiran
View Brand Information
FDA approval date: November 19, 2025
Form: Injection

What is Redemplo (Plozasiran)?

REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome . REDEMPLO is an apolipoprotein C-III -directed small interfering ribonucleic acid indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome .

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Enrollment Status: Recruiting
Publish Date: June 10, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either...

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)
Enrollment Status: Recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016...

View All Clinical Trials

Related Latest Advances

Correction to 'Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study'.
Correction to 'Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study'.
Journal: Alimentary pharmacology & therapeutics
Published: June 13, 2026
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.
Journal: The Annals of pharmacotherapy
Published: June 06, 2026
Translating Lipoprotein Genetics Into New Therapies.
Translating Lipoprotein Genetics Into New Therapies.
Journal: Circulation research
Published: June 04, 2026
View All Latest Advances